In this episode I visit with Dr. Eugene Yang to discuss the update to hypertension guidelines published in 2017 by the ACC/AHA. I asked him what were the major changes and which patients should be treated to a target of <130/80 and practical aspects to management.
Links:
Following up on our last discussion with Dr. Daniel Lenihan, we address the subject of immune checkpoint inhibitors and the associated cardio-toxicities. Immune checkpoint inhibitors “ease the brakes” of the immune system leading to dramatic improvements in some cancers, but rarely this can lead to profound cardiovascular compromise. Hyperlinks to references on apcardiology.com
References:
Cardiovascular toxicities associated with immune checkpoint inhibitors
Fulminant myocarditis with combination immune checkpoint blockade
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
I visited with Dr. Daniel Lenihan and spoke with him about cardio-oncology and some of the common issues and concerns that arise. Cardio-oncology is a very broad field and revolves around managing cardiovascular toxicities associated with cancer therapies. We discuss the classic example of anthracycline toxicity and touch on some of the newer therapies (immune checkpoint inhibitors).
Preparing the Cardiovascular Workforce to Care for Oncology Patients
